Amyotrophic lateral sclerosis

Clinical Trials in Neurology: Design, Conduct, Analysis

Volumn , Issue , 2012, Pages 273-283

  Atassi, Nazem ^a   Schoenfeld, David ^a   Cudkowicz, Merit ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84921667654     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139032445.025     Document Type: Chapter

References (51)

1. Lanka V, Cudkowicz M. Therapy development for ALS: Lessons learned and path forward. Amyotroph Lateral Scler 2008; 9: 131-40.
2. Bensimon G, Lacomblez L, and Meininger V. The ALSRSG. A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. NEngl JMed 1994; 330: 585-91.
3. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59-62.
4. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-F70. Neuron2011; 72(2): 257-68.
5. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol2009; 65(S1): S3-S9.
6. Cleveland DW and Rothstein JD. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nature Reviews Neuroscience 2001; 2(11): 806-19.
7. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321: 1218-21.
8. Scott S, Kranz JE, Cole J, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008; 9:4-15.
9. Cedarbaum J, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporated assessments of respiratory function. J Neurol Sci 1999; 169: 13-21.
10. Qureshi M, Schoenfeld DA, Paliwal Y, et al. The natural history of ALS is changing: Improved survival. Amyotroph Lateral Scler 2009; 10: 324-31.
11. McGuire V, Longstreth Jr W, Koepsell T, et al. Incidence of amyotrophic lateral sclerosis in three counties in western Washington State. Neurology 1996; 47: 571-3.
12. Kurtzke J and Kurland L. The epidemiology of neurologic disease. In: Joynt R, editor. Clinical Neurology. Philadelphia, J.B. Lippincot. 1989; 1-43.
13. Kurtzke JF. Risk factors in amyotrophic lateral sclerosis. Adv Neurol 1991; 56: 245-70.
14. Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 2000; 57: 1171–6.
15. El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 2000; 57: 1171-6.
16. Brooks B, Miller R, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler OtherMotor Neuron Disord 2000; 15:293-9.
17. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006;66:647-53.
18. Conte A, Media F, Luigetti M, et al. Survival in ALS patients after tracheostomy. 20th Symposium on ALS/MND. Berlin. 2009.
19. Traynor BJ, Zhang H, Shefner JM, et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004; 63:1933-5.
20. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003; 61:456-64.
21. Goonetilleke A, Modarres-Sadeghi H and Guiloff R. Accuracy, reproducibility, and variability of hand-held dynamometry in motor neuron disease. J Neurol Neurosurg Psych 1994; 57: 326-32.
22. Beck M, Giess R, Wurffel W, et al. Comparison of maximal voluntary isometric contraction and Drachman’s hand-held dynamometry in evaluating patients with amyotrophic lateral sclerosis. Muscle Nerve 1999; 22: 1265-70.
23. Raoul C, Estevez A, Nishimune H, et al. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 2002; 35: 1067-83. Chapter 24: Amyotrophic lateral sclerosis.
24. Shefner J, Rutkove SB, David W, et al. Modified incremental motor unit estimation in a longitudinal natural history study of subjects with ALS. 20th International Symposium on ALS/MND. Berlin. 2009.
25. Kaufmann P, Levy G, Montes J, et al. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotrophic Lateral Sclerosis 2007; 8: 42-6.
26. Kasarskis EJ, Dempsey-Hall L, hompson MM, et al. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 50-4.
27. Appel V, Stewart S, Smith G, et al. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987; 22: 328-33.
28. Simmons Z, Felgoise SH, Bremer BA, et al. The ALSSQOL: Balancing physical and nonphysical factors in assessing quality of life in ALS. Neurology 2006; 67: 1659-64.
29. Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis 2009; 10: 99-106.
30. Turner MR, Kiernan MC, Leigh PN, et al. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009; 8: 94-109.
31. Finkelstein D and Schoenfeld D. Combining mortality and longitudinal measures in clinical trials. Stat Med1999; 18:1341-54.
32. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011; 17(12): 1652-6.
33. Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2010; 11:259-65.
34. Schoenfeld DA and Cudkowicz M. Design of phase II ALS clinical trials. Amyotrophic Lateral Sclerosis 2008; 9: 16-23.
35. Petra K, John LPT, Gilberto L, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Annals of Neurology 2009; 66: 235-44.
36. Gordon PH, Cheung Y-K, Levin B, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotrophic Lateral Sclerosis 2008; 9: 212-22.
37. Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006; 66: 660-3.
38. Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007; 69: 776-84.
39. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol2007; 6: 1045-53.
40. Cudkowicz M, Greenblatt D, Shefner J, et al.Ceftriaxone in ALS: results of stages 1 and 2 of an adaptive design safety, pharmacokinetic and efficacy trial. 20th International Symposium on ALS/MND. Berlin. 2009.
41. Lacomblez L, Bensimon G, Leigh P, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425-31.
42. Aggarwal S and Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008; 5: 516-27.
43. Bedlack RS, Pastula D, Welsh E, et al. Scrutinizing enrollment in ALS clinical trials: Room for improvement? Amyotroph Lateral Scler 2008; 9:257-65.
44. Czaplinski A, Yen AA, Simpson EP, et al. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: Is the natural history of amyotrophic lateral sclerosis changing? Arch Neurol 2006; 63:1139-43.
45. Testa D, Lovati R, FerrariniM, etal. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 208-12.
46. Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry 2003; 74: 1258-61.
47. Dattwyler RJ, Halperin JJ, Pass H, et al. Ceftriaxone as effective therapy in refractory lyme disease. J Inf Dis1987; 155:1322-4.
48. Forshew DA and Bromberg MB. A survey of clinicians’ practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord2003; 4:258-63.
49. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73: 1218-26.
50. Batshaw M, MacArthur R, and Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138(Suppl 1): S46-55.
51. Leigh N, Groups atNAaEAI-S. The treatment of ALS with recombinant insulin-like growth factor (rhIGF-1): pooled analysis of two clinical trials. Neurology 1997; 1997(Suppl 1): A217-A8.